Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study.
about
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisStatins for the primary prevention of cardiovascular diseasePathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesisEffect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials.Renal failure (chronic)Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: a cohort studyEffect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis.Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysisContrasting Cholesterol Management Guidelines for Adults with CKD.Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis.Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-AnalysisHypertension and low HDL cholesterol were associated with reduced kidney function across the age spectrum: a collaborative studyPhysician utilization, risk-factor control, and CKD progression among participants in the Kidney Early Evaluation Program (KEEP).Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.Statins in patients with chronic kidney disease: why, who and when?Statins, inflammation and kidney disease.HMG-CoA reductase inhibitors in chronic kidney disease.Statins in chronic kidney disease: cardiovascular risk and kidney function.Meta-analysis of statins in chronic kidney disease: who benefits?Lipid lowering in renal disease.The lipid story in chronic kidney disease: a long story with a happy end?Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro.Statin Use and Survival After Acute Kidney Injury.Approach to cardiovascular disease prevention in patients with chronic kidney disease.
P2860
Q24194514-922AE8BE-E55C-4618-AFF1-12B6F8741AF7Q24201513-EF267EC2-24F3-4DD7-868D-0490F4E70F53Q30235369-4FA5E77F-B602-46C2-9CF7-45F0442482CEQ33588706-A3BBA2BD-F779-46F3-B3F2-CC8460A97BEBQ33910618-5CFE67F7-A043-4A2A-8357-9F0C8E0F5E1AQ34019491-FCDBF7ED-C46D-4B26-ABE9-7C54D30400F8Q34613884-E05051A8-F7FA-4F81-86B1-D25EF15DD9F7Q34979484-5040F164-5365-444C-A428-B0588A02FBFBQ35030586-2E5ECAF5-B46F-4420-93DB-DB444DBC175CQ35550614-F3148271-8E1B-4808-B4A6-D72B43077448Q35576102-31399BA6-A394-42B3-ACEE-3F3599DA2858Q35685253-E5FC705B-90F2-4EAE-B9F6-DED314FE8DC7Q36604880-455F7F2F-3B91-4856-84DE-A388795A2C29Q36845662-B7C9226D-8D71-436A-99E5-25F74C134533Q37638675-3B4B707F-5726-400D-9C9A-8D9D3B8DBA54Q37803236-B9AB6ED5-3A21-4A91-9A68-E39914B67529Q37883015-5CB78F44-B3B2-4B3C-A4F6-BA030B5F0992Q38131449-BA76413C-6920-4BA6-BAFF-1602CCAD26DAQ38176142-E49EC3B1-02FF-489F-9AF1-0523F30FB6B2Q38878462-81243266-0026-4144-A244-6E06D5D59413Q41690923-A255AC1D-E116-43A6-AD49-FBC310E80E77Q42912193-5E6B1642-2C03-47AA-A70E-93EF27FE5056Q46243045-3EE677A8-6B65-4F26-AE5C-FDB21F3B9BE1Q47161734-522593CE-60C9-4FDB-9D8A-9EF4F3B0C241Q49136022-CAA91AC2-E90F-4665-BBBE-43B24728E3D3
P2860
Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Effect of lovastatin on primar ...... erosclerosis Prevention Study.
@ast
Effect of lovastatin on primar ...... erosclerosis Prevention Study.
@en
Effect of lovastatin on primar ...... erosclerosis Prevention Study.
@nl
type
label
Effect of lovastatin on primar ...... erosclerosis Prevention Study.
@ast
Effect of lovastatin on primar ...... erosclerosis Prevention Study.
@en
Effect of lovastatin on primar ...... erosclerosis Prevention Study.
@nl
prefLabel
Effect of lovastatin on primar ...... erosclerosis Prevention Study.
@ast
Effect of lovastatin on primar ...... erosclerosis Prevention Study.
@en
Effect of lovastatin on primar ...... erosclerosis Prevention Study.
@nl
P2093
P2860
P1476
Effect of lovastatin on primar ...... erosclerosis Prevention Study.
@en
P2093
Giovanni Targher
Jessica Kendrick
Joann Lindenfeld
Michel Chonchol
Thomas Cook
P2860
P356
10.1053/J.AJKD.2009.09.020
P577
2009-11-22T00:00:00Z